6071-92-7

Basic information

• Product Name: (1-methylpiperidin-4-yl)(diphenyl)methanol
• Synonyms: .alpha.,.alpha.-Diphenyl-1-methyl-4-piperidinemethanol; 4-Piperidinemethanol, .alpha.,.alpha.-diphenyl-1-methyl-
• CAS NO: 6071-92-7
• Molecular Formula: C₁₉H₂₃NO
• Molecular Weight: 281.392
• Mol File: 6071-92-7.mol

Chemical Properties

• Boiling Point: 421.5°C at 760 mmHg
• Flash Point: 202°C
• Density: 1.093g/cm³
• Vapor Pressure: 7.38E-08mmHg at 25°C
• Refractive Index: 1.583
• CAS DataBase Reference: (1-methylpiperidin-4-yl)(diphenyl)methanol(CAS DataBase Reference)
• NIST Chemistry Reference: (1-methylpiperidin-4-yl)(diphenyl)methanol(6071-92-7)
• EPA Substance Registry System: (1-methylpiperidin-4-yl)(diphenyl)methanol(6071-92-7)

Safety Data

• Hazardous Substances Data: 6071-92-7(Hazardous Substances Data)

Usage

Uses

Used in Chemical Reactions and Organic Synthesis:
(1-methylpiperidin-4-yl)(diphenyl)methanol is used as a reactant in various chemical reactions and organic synthesis processes, leveraging its unique structure and reactivity to form a range of different compounds.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, (1-methylpiperidin-4-yl)(diphenyl)methanol is used as a precursor or intermediate in the development of new drugs and medications. Its structural features may contribute to the creation of novel therapeutic agents with specific pharmacological properties.
Used in Drug Development:
(1-methylpiperidin-4-yl)(diphenyl)methanol is used as a building block in drug development, potentially leading to the discovery of new pharmaceutical compounds with improved efficacy and safety profiles.
Safety and Handling:
It is crucial to handle (1-methylpiperidin-4-yl)(diphenyl)methanol with care due to its potential health and safety hazards. Proper safety measures should be implemented to minimize risks associated with its use in chemical processes and pharmaceutical applications.

Upstream product

• 1690-75-1 1-methyl-piperidine-4-carboxylic acid methyl ester 
• 591-51-5 phenyllithium 
• 92040-00-1 (1-methylpiperidin-4-yl)(phenyl)methanone 
• 60-29-7 diethyl ether 
• 107054-93-3 (4-chloro-1-methyl-[4]piperidyl)-phenyl ketone 
• 50-00-0 formaldehyd 
• 115-46-8 C₁₈H₂₁NO 
• 20735-04-0 (1,2,3,6-tetrahydro-1-methylpyridin-4-yl)diphenylmethanol 
• 92196-29-7 (1-methylpiperidin-4-yl)(phenyl)methanol 
• 68947-43-3 1-methylpiperidine-4-carboxylic acid 
• 1557-31-9 N-methyl-4-benzylpiperidine 
• 7440-32-6 titanium 
• 58258-01-8 4-diphenylmethoxypiperidine 
• 5570-77-4 4-chloro-1-methylpiperidine 

Downstream Products

• 6071-93-8 NSC 31633 
• 5704-22-3 4-(diphenylmethyl)-1-methylpiperidine 
• 112818-77-6 ethyl 4-(hydroxydiphenylmethyl)piperidine-1-carboxylate 
• 950054-08-7 (1-benzenesulfonylpiperidin-4-yl)diphenylmethanol 
• 852860-46-9 diphenyl[1-(toluene-4-sulfonyl)piperidin-4-yl]methanol 
• 1152785-34-6 [1-(2-nitrobenzenesulfonyl)piperidin-4-yl](diphenyl)methanol 
• 1164112-38-2 (1-(3,5-dimethyl-2,3-dihydro-isoxazole-4-sulfonyl)-piperidin-4-yl)-diphenyl-methanol 
• 1164112-40-6 [1-(4-propylbenzenesulfonyl)piperidin-4-yl]diphenylmethanol 
• 1164112-41-7 diphenyl[1-(propane-2-sulfonyl)piperidin-4-yl]methanol 
• 1032324-37-0 [1-((4-chloro-2-fluorobenzene)sulfonyl)piperidin-4-yl]diphenylmethanol 
• 1164112-42-8 [1-(butane-1-sulfonyl)piperidin-4-yl]diphenylmethanol 
• 1164112-43-9 (1-chloromethanesulfonylpiperidin-4-yl)diphenylmethanol 
• 1164112-44-0 diphenyl(1-phenylmethanesulfonylpiperidin-4-yl)methanol 
• 1164112-45-1 [1-(3-nitro-benzene-1-sulfonyl)piperidin-4-yl]diphenylmethanol 

Relevant articles and documents

Steric structure–activity relationship of cyproheptadine derivatives as inhibitors of histone methyltransferase Set7/9

Set7/9 is a histone lysine methyltransferase, but it is also thought to be involved in a wide variety of pathophysiological functions. We previously identified cyproheptadine, which has a characteristic butterfly-like molecular conformation with bent tricyclic dibenzosuberene and chair-form N-methylpiperidine moieties, as a Set7/9 inhibitor. In this work, we synthesized several derivatives in order to examine the steric structure–inhibitory activity relationship. We found that even a small change of molecular shape due to reduction or replacement of the 10,11-olefinic bond of the tricyclic ring generally resulted in a drastic decrease of the inhibitory activity. Our results should be useful not only for development of more potent and selective inhibitors, but also for the construction of novel inhibitor scaffolds.

Synthesis and in vitro antiproliferative activity of diphenyl(sulphonylpiperidin-4-yl)methanol derivatives

A series of novel diphenyl(piperidin-4-yl)methanol derivatives 10(a-n) were synthesized and characterized by 1H NMR, LC/MS, FTIR, and elemental analyses. All the synthesized compounds were evaluated for cell proliferation by MTT assay. The antiproliferative effects of the synthesized compounds were tested against viable human skin fibroblast cell line and carcinoma cell lines, namely HeLa cells, HT-29 cells, MCF-7 cells, and HepG-2 cells in comparing the positive and negative control. Among the synthesized compounds, (10b) and (10g) have been identified as potent antiproliferative agents.

Treatment of CNS disorders using CNS target modulators

The invention is directed to compositions and methods useful for treating Central Nervous System (CNS) disorders. Furthermore, the invention provides compositions and methods of treating sleep disorders. More specifically, the invention is directed to the compositions and use of derivatized, histamine antagonists for the treatment of sleep disorders.

TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS

The invention is directed to compositions used for treating Central Nervous System (CNS) disorders. In addition, the invention provides convenient methods of treatment of a CNS disorder. Furthermore, the invention provides methods of treating sleep disorders using compositions that remain active for a discrete period of time to reduce side effects. More specifically, the invention is directed to the compositions and use of derivatized, e.g., ester or carboxylic acid derivatized, antihistamine antagonists for the treatment of sleep disorders.

Synthesis of α,α-diphenyl-4-piperidine-methanol (azacyclonol), an intermediate for terfenadine

Starting from diphenyl 4-pyridylcarbinol (2), synthesis of azacyclonol (7) has been carried out by a series of reactions involving quarternisation, borohydride reduction, catalytic transfer hydrogenation and N-demethylation.

Structure-activity relationships within a series of analogues of the histamine H1-antagonist terfenadine

A number of terfenadine derivatives including terfenadine enantiomers were synthesized and tested for histamine H1-receptor affinity. No significant differences in H1 activity were found between terfenadine enantiomers. Qualitative structure-activity relationship studies identified the α,α-diphenyl-4-piperidinomethanol moiety as the pharmacophore for the H1 activity of this group of compounds. The major role of the phenylbutanol moiety in terfenadine seems to be preventing the compound from crossing the blood-brain barrier.